May 23, 2015
Below are current clinical trials.491 studies in Cancer
(open studies only).
Filter this list of studies by location, status and more.
The purpose of this study is to determine if two-dimensional speckle tracking echocardiography (2D-STE) derived-strain can detect early myocardial dysfunction and thus predict cardiotoxicity in sarcoma subjects undergoing anthracycline therapy and to compare three dimensional speckle tracking echocardiography (3D-STE) to 2D-STE in the same group of patients.
The purpose of this study is to evaluate the safety, disease response, and drug /body interactions of rSIFN-co at different dose levels to demonstrate optimal dosage for patients with advanced solid tumors.
This partially randomized phase Ib/II trial studies the side effects and best dose of taselisib when given together with enzalutamide and to see how well they work in treating patients with androgen receptor positive triple-negative breast cancer that has spread to other places in the body. Taselisib is a PI3K inhibitor. The PI3K pathway is involved is cancer growth. Androgen may cause the growth of tumor cells. Enzalutamide may stop the growth of tumor cells by blocking the androgen receptor from working. Giving taselisib with enzalutamide may be a better treatment for patients with breast cancer.
The purpose of this research is to optimize and evaluate the efficacy of a hybrid imaging and quantitative viscoelasticity measurement tool for breast cancer detection and monitoring.
The purpose of the study is to explore the safety and efficacy of CLT-008 as an extra supportive care measure during induction chemotherapy for patients with acute myeloid leukemia (AML).
Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.
This study is designed to evaluate PFS endpoint for acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia.
The long-term goal of this research program is to clarify the potential mutation causing and cancer causing risk posed by clinical magnetic resonance imaging (MRI).
This is an open-label, Phase 1b, platform study in subjects with advanced or metastatic solid tumors. The study will be divided into 2 parts (Part 1a and Part 1b). Part 1a will evaluate a JAK inhibitor with JAK1 selectivity (INCB039110) in combination with an IDO1 inhibitor (epacadostat; INCB024360; Group A) and INCB039110 in combination with a PI3K-delta inhibitor (INCB050465; Group B) to determine the MTD or PAD and the recommended Part 1b doses for each combination. Once the recommended dose has been identified for each treatment group in Part 1a, subjects with advanced solid tumors will be enrolled into expansion cohorts based upon prior treatment history with a PD-1 pathway-targeted agent (Part 1b).
This study will examine the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer. SGN-LIV1A will be given every 3 weeks alone or in combination with trastuzumab.
La Crosse, Wis., Rochester, Minn., Mankato, Minn.
This randomized phase III trial studies olaparib or cediranib maleate and olaparib to see how well they work compared with standard platinum-based chemotherapy in treating patients with platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer that has come back. Olaparib and cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may stop the growth of ovarian, fallopian tube, or primary peritoneal cancer by blocking the growth of new blood vessels necessary for tumor growth. Drugs used in chemotherapy, such as carboplatin, paclitaxel, gemcitabine hydrochloride, and pegylated liposomal doxorubicin hydrochloride work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether olaparib or cediranib maleate and olaparib is more effective than standard platinum-based chemotherapy in treating patients with platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.
- Deaths and mortality. Centers for Disease Control and Prevention. http://www.cdc.gov/nchs/fastats/deaths.htm. Accessed April 23, 2015.
- Cancer: All sites. Surveillance Epidemiology and End Results. http://seer.cancer.gov/statfacts/html/all.html. Accessed April 23, 2015.
- Symptoms. National Cancer Institute. http://www.cancer.gov/cancertopics/diagnosis-staging/symptoms. Accessed April 23, 2015.
- Kushi LH, et al. American Cancer Society guidelines on nutrition and physical activity for cancer prevention: Reducing the risk of cancer with healthy food choices and physical activity. CA: A Cancer Journal for Clinicians. 2012;62:30.
- Niederhuber JE, et al., eds. Genetic and epigenetic alterations in cancer. In: Abeloff's Clinical Oncology. 5th ed. Philadelphia, Pa.: Churchill Livingstone Elsevier; 2014. http://www.clinicalkey.com. Accessed April 23, 2015.
- Ulcerative colitis. National Institute of Diabetes and Digestive and Kidney Diseases. http://digestive.niddk.nih.gov/ddiseases/pubs/colitis/index.htm. Accessed April 23, 2015.
- NINDS paraneoplastic syndromes information page. National Institute of Neurological Disorder and Stroke. http://www.ninds.nih.gov/disorders/paraneoplastic/paraneoplastic.htm. Accessed April 23, 2015.
- Deng GE, et al. Evidence-based clinical practice guidelines for integrative oncology: Complementary therapies and botanicals. Journal of the Society for Integrative Oncology. 2009;7:85.
- Taking time: Support for people with cancer. National Cancer Institute. http://cancer.gov/cancertopics/takingtime. Accessed April 23, 2015.
- Moynihan TJ (expert opinion). Mayo Clinic, Rochester, Minn. May 1, 2015.
- Hypercalcemia (high level of calcium in the blood). Merck Manual Home Edition. http://www.merckmanuals.com/home/hormonal-and-metabolic-disorders/electrolyte-balance/hypercalcemia-high-level-of-calcium-in-the-blood. Accessed April 23, 2015.
- What is cancer? National Cancer Institute. http://www.cancer.gov/cancertopics/what-is-cancer. Accessed April 23, 2015.
- Cancer prevention overview (PDQ). National Cancer Institute. http://www.cancer.gov/cancertopics/pdq/prevention/overview/patient/page1/AllPages. Accessed April 23, 2015.
- The genetics of cancer. National Cancer Institute. http://www.cancer.gov/cancertopics/causes-prevention/genetics. Accessed April 23, 2015.
- Understanding cancer risk. Cancer.Net. http://www.cancer.net/navigating-cancer-care/prevention-and-healthy-living/understanding-cancer-risk. Accessed April 23. 2015.
- Cancer screening overview (PDQ). National Cancer Institute. http://www.cancer.gov/cancertopics/pdq/screening/overview/HealthProfessional. Accessed April 23, 2015.
- Diagnosis. National Cancer Institute. http://www.cancer.gov/cancertopics/diagnosis-staging/diagnosis. Accessed April 23, 2015.
- Staging. National Cancer Institute. http://www.cancer.gov/cancertopics/diagnosis-staging/staging. Accessed April 23, 2015.
- Making decisions about cancer treatment. Cancer.Net. http://www.cancer.net/navigating-cancer-care/how-cancer-treated/making-decisions-about-cancer-treatment. Accessed April 23, 2015.
- How cancer is treated. Cancer.Net. http://www.cancer.net/navigating-cancer-care/how-cancer-treated. Accessed April 23, 2015.